AU785445C - Anti-EphA2 antibodies as a cancer diagnostic - Google Patents

Anti-EphA2 antibodies as a cancer diagnostic

Info

Publication number
AU785445C
AU785445C AU67843/00A AU6784300A AU785445C AU 785445 C AU785445 C AU 785445C AU 67843/00 A AU67843/00 A AU 67843/00A AU 6784300 A AU6784300 A AU 6784300A AU 785445 C AU785445 C AU 785445C
Authority
AU
Australia
Prior art keywords
epha2
antibody
cells
detecting
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU67843/00A
Other languages
English (en)
Other versions
AU785445B2 (en
AU6784300A (en
Inventor
Katherine E. Kilpatrick
Michael Scott Kinch
Nicole Dodge Zantek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Glaxo Group Ltd
University of North Carolina at Chapel Hill
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, University of North Carolina at Chapel Hill, Purdue Research Foundation filed Critical Glaxo Group Ltd
Publication of AU6784300A publication Critical patent/AU6784300A/en
Application granted granted Critical
Publication of AU785445B2 publication Critical patent/AU785445B2/en
Publication of AU785445C publication Critical patent/AU785445C/en
Assigned to PURDUE RESEARCH FOUNDATION reassignment PURDUE RESEARCH FOUNDATION Alteration of Name(s) in Register under S187 Assignors: GLAXO GROUP LIMITED, PURDUE RESEARCH FOUNDATION, UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU67843/00A 1999-08-17 2000-08-17 Anti-EphA2 antibodies as a cancer diagnostic Ceased AU785445C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14925999P 1999-08-17 1999-08-17
US60/149259 1999-08-17
PCT/US2000/022669 WO2001012840A2 (en) 1999-08-17 2000-08-17 Anti-epha2 antibodies as a cancer diagnostic

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007202091A Division AU2007202091A1 (en) 1999-08-17 2007-05-10 Anti-epha2 antibodies as a cancer diagnostic

Publications (3)

Publication Number Publication Date
AU6784300A AU6784300A (en) 2001-03-13
AU785445B2 AU785445B2 (en) 2007-06-14
AU785445C true AU785445C (en) 2008-01-31

Family

ID=22529464

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67843/00A Ceased AU785445C (en) 1999-08-17 2000-08-17 Anti-EphA2 antibodies as a cancer diagnostic

Country Status (8)

Country Link
EP (2) EP2312316A1 (enExample)
JP (3) JP4948728B2 (enExample)
AT (1) ATE483978T1 (enExample)
AU (1) AU785445C (enExample)
CA (1) CA2382655A1 (enExample)
DE (1) DE60045075D1 (enExample)
ES (1) ES2357296T3 (enExample)
WO (1) WO2001012840A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
AU2001256970C1 (en) 2000-03-31 2008-07-03 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
WO2003004529A2 (en) * 2001-07-02 2003-01-16 Licentia Ltd. Ephrin-tie receptor materials and methods
CA2461877A1 (en) * 2001-09-28 2003-04-10 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
EP1453530A2 (en) * 2001-11-09 2004-09-08 Neuronova AB Method of proliferation in neurogenic regions
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
WO2003094859A2 (en) * 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
CA2486615A1 (en) 2002-05-23 2003-12-04 Purdue Research Foundation Low molecular weight protein tyrosine phosphatase (lmw-ptp) as a diagnostic and therapeutic target
JP4838720B2 (ja) 2003-05-13 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 転移および転移がもたらす骨格関連現象を調節する方法
CA2542631A1 (en) * 2003-10-15 2005-04-28 Medimmune, Inc. Listeria-based epha2 vaccines
EP1778726A4 (en) 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
KR101363252B1 (ko) * 2005-02-04 2014-02-13 레이븐 바이오테크놀로지스, 인코퍼레이티드 Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
WO2009028639A1 (ja) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体
JP6069806B2 (ja) * 2013-02-13 2017-02-01 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP6399013B2 (ja) * 2016-02-18 2018-10-03 トヨタ自動車株式会社 化学蓄熱器の制御装置
WO2018034332A1 (ja) * 2016-08-19 2018-02-22 国立大学法人東京大学 ＥｐｈＡ２ Ｎ末端フラグメント抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514554A (en) 1991-08-22 1996-05-07 Becton Dickinson And Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
US5457048A (en) * 1993-12-03 1995-10-10 La Jolla Cancer Research Foundation Eph-related tyrosine kinases, nucleotide sequences and methods of use
US5876949A (en) 1995-05-31 1999-03-02 The Trustees Of The University Of Pennsylvania Antibodies specific for fragile X related proteins and method of using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ZANTEK ET AL, MOL. BIOL. OF CELL (1997) V.8 (SUPP) P. 134A *
ZANTEK ET AL, MOL. BIOL. OF CELL (1998) V.9 (SUPP) P. 134A *
ZANTEK ET AL, PROC. OF AM. ASSOC. CANCER RES (99)V.40 P 687 *

Also Published As

Publication number Publication date
ATE483978T1 (de) 2010-10-15
EP2312316A1 (en) 2011-04-20
EP1210603A2 (en) 2002-06-05
JP2007291140A (ja) 2007-11-08
ES2357296T3 (es) 2011-04-25
WO2001012840B1 (en) 2001-09-27
AU785445B2 (en) 2007-06-14
AU6784300A (en) 2001-03-13
JP2003507023A (ja) 2003-02-25
JP4948728B2 (ja) 2012-06-06
DE60045075D1 (de) 2010-11-18
WO2001012840A3 (en) 2001-05-03
CA2382655A1 (en) 2001-02-22
JP2012103264A (ja) 2012-05-31
EP1210603B1 (en) 2010-10-06
WO2001012840A2 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
US20070161064A1 (en) Antibodies as a cancer diagnostic
AU785445C (en) Anti-EphA2 antibodies as a cancer diagnostic
US7090983B1 (en) Methods for detecting early cancer
WO2007124361A2 (en) Soluble b7-h1
EP2403880A1 (en) Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
US9625461B2 (en) Method of detecting cancer using delta-catenin
CA2662012C (en) Boris isoforms and methods of detecting and treating disease
EP1930445B1 (en) Kit and method for detection of urothelial cancer
JP2008309612A (ja) 卵巣癌の検出方法及び検出用キット
US20050214301A1 (en) Antibodies specific for BCR-ABL fusion protein and uses thereof
JP2012531606A (ja) Δ１３３ｐ５３βを用いた転移癌を有する素因があると思われる被験体の検査方法
AU2011253563A1 (en) Anti-epha2 antibodies as a cancer diagnostic
AU2007202091A1 (en) Anti-epha2 antibodies as a cancer diagnostic
JP4451784B2 (ja) 前立腺癌腫瘍マーカー
US20130203059A1 (en) Method for Diagnosis of Bladder Cancer and Related Kits
AU2012326434A1 (en) Predictive biomarkers for breast cancer
US8445220B2 (en) Methods of diagnosing latent and active malignancies
Class et al. Patent application title: Method for Diagnosis of Bladder Cancer and Related Kits Inventors: Antonio Feliciello (Parete, IT) Luigi Insabato (Napoli, IT) Assignees: Topogen, Inc.

Legal Events

Date Code Title Description
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 20000817 TO 20001217 IN WHICH TO AMEND THE SPECIFICATION TO THE REQUIREMENTS OF REGULATION 1.5(1) IN ORDER TO COMPLY WITH SECTION 6(C) HAS BEEN LODGED

MK3 Application lapsed section 142(2)(c) - examination deferred under section 46 no request for examination
TH Corrigenda

Free format text: IN VOL 18, NO 3, PAGE(S) 73 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO PATENT APPLICATION'S 67843/00 AND 67844/00